# Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

## TL;DR

This paper presents an updated Chinese expert consensus on the standardized diagnosis and treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations.

## Contribution

The paper updates the 2023 consensus with new clinical data and treatment strategies for EGFR exon 20 insertion mutations in NSCLC.

## Key findings

- The consensus includes updated recommendations for disease detection and treatment.
- New targeted drugs and clinical trial data are incorporated into the guidelines.
- The document aims to improve clinical decision-making for this rare mutation type.

## Abstract

表皮生长因子受体（epidermal growth factor receptor, EGFR）20外显子插入（exon 20 insertion, ex20ins）突变非小细胞肺癌（non-small cell lung cancer, NSCLC）的规范化诊疗在《EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识（2023版）》中进行了阐述，提高了临床医生对该罕见靶点的关注。随着疾病领域探索的深入及新型靶向药物的获批，EGFR ex20ins NSCLC的诊疗策略也随之更新。本共识在2023版中国专家共识的基础上进行更新，专家组通过参考国内外文献及临床数据并结合专家自身临床经验，分别从疾病认知、疾病检测、疾病治疗和新型靶向药物研发现状等方面更新共识性建议，以期更好地为临床医师提供用药参考。

CSCO《Guidelines of NSCLC 2024》first-line treatment of stage IV NSCLC without driver genes

Clinical studies in first-line treatment of patients with EGFR ex20ins mutated NSCLC

Clinical studies in second-line and later-line treatment of patients with EGFR ex20ins mutated NSCLC